Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered long-acting injectable drug formulation platform cutting development from 5 years to 2; $12M Series A with Eli Lilly investment competing in microsphere CDMO development.
Persist AI is a pharmaceutical formulation company operating an AI-powered drug formulation platform with robotic cloud lab capabilities — specializing in the development of long-acting injectable (LAI) microsphere formulations that can deliver drug release over weeks or months (up to one year), addressing the adherence challenges of daily oral medications for chronic conditions including mental health, addiction, HIV, contraception, and oncology. Founded in 2022 and backed by $16 million including a $12 million Series A led by Spero Ventures with participation from Eli Lilly, Persist AI accelerates drug development timelines by approximately 50%, reducing typical 5-year formulation development to 2 years.\n\nPersist AI's platform combines AI-driven formulation design (predicting which polymer/drug/process combinations will achieve target release profiles) with robotic laboratory execution (automated synthesis and testing of formulation candidates) and analytics that identify optimal formulations faster than traditional trial-and-error approaches. The microsphere technology encapsulates drug molecules in biodegradable polymer spheres that gradually release the drug as the polymer degrades — a proven technology (Risperdal Consta, Lupron Depot) but one that takes years to develop with traditional methods. Eli Lilly's participation as an investor signals pharma validation of the platform approach.\n\nIn 2025, Persist AI competes in the drug formulation and CDMO (contract development and manufacturing) market with EVO Pharma, Polymeropoulos (a long-acting injectable specialist), and larger CDMOs including Lonza and Catalent for LAI microsphere development services. The long-acting injectable market is growing as mental health conditions (schizophrenia, bipolar) see improved outcomes with LAI antipsychotics that eliminate the adherence problem — patients who receive monthly or quarterly injections have significantly better medication compliance than those taking daily pills. The 2025 strategy focuses on growing pharma company partnerships for LAI development projects, advancing internal pipeline candidates toward clinical trials, and building the manufacturing scale-up capabilities needed for commercial supply.
Santa Clara cybersecurity platform (NASDAQ: PANW) $8.0B FY2024 revenue (+16%); platformization 3,600+ customers, Cortex XSIAM AI SOC, $4.2B NGSSAR +42%, competing with CrowdStrike and Microsoft Defender.
Palo Alto Networks, Inc. is a Santa Clara, California-based cybersecurity platform company — publicly traded on the NASDAQ (NASDAQ: PANW) as an S&P 500 Information Technology component — providing network security, cloud security, and AI-driven security operations through three integrated security platforms: Strata (network security — next-generation firewalls, SD-WAN, Zero Trust Network Access), Prisma Cloud (cloud security posture management, cloud workload protection, CSPM/CWPP), and Cortex (AI-driven security operations — XSIAM extended security intelligence and automation management, XDR endpoint detection and response, XSOAR security orchestration) through approximately 15,000 employees worldwide. In fiscal year 2024 (ending July 2024), Palo Alto Networks reported revenues of $8.0 billion (+16% year-over-year), with next-generation security Annual Recurring Revenue (ARR — Prisma Cloud and Cortex subscriptions) growing 42% to $4.2 billion as large enterprise and government customers consolidated security toolsets onto Palo Alto Networks' platform versus maintaining dozens of point solution security vendors. CEO Nikesh Arora (joined 2018 from SoftBank as Chairman and CEO) has executed the "platformization" strategy — convincing large enterprise security buyers to replace 10-15 individual security vendors (email security, endpoint protection, cloud workload protection, network detection) with a consolidated Palo Alto Networks platform contract that provides 80% of point-solution capabilities at 50% of the total cost — using the first-year transition economics to accelerate platform adoption through deferred commitment offers (paying a lower platform price in year 1 in exchange for multi-year platform commitment in years 2-4).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.